PACAP Is Protective in a Rat Model of Retinopathy of Prematurity
Authors:
- 25 August 2016
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 60 (2) , 179-185
Abstract
The oxygen-induced retinopathy (OIR) is a well-established rodent model of retinopathy of prematurity (ROP), which is one of the most common causes of childhood visual impairment affecting preterm babies. Pituitary adenylate cyclase-activating polypeptide (PACAP) is known to have neuroprotective effects. Several studies have revealed the presence of PACAP and its receptors in the retina and reported its protective effects in ischemic and diabetic retinopathy. In this study, we investigated whether PACAP administration can influence the vascular changes in the rat OIR model. OIR was generated by placing the animals in daily alternating 10/50 oxygen concentrations from postnatal day (PD) 0 to PD14 then returned them to room air. Meanwhile, animals received PACAP or saline intraperitoneally or intravitreally from PD1 to PD8 or on PD11, PD14, and PD17, respectively. On PD19 ± 1, the retinas were isolated and the vessels were visualized by isolectin staining. The percentage of avascular to whole retinal areas and the number of branching points were measured. Change in cytokine expression was also determined. Intravitreal treatment with PACAP remarkably reduced the extent of avascular area compared to the non- and saline-treated OIR groups. Intraperitoneal PACAP injection did not influence the vascular extent. Retinal images of room-air controls did not show vascular alterations. No changes in the number of vessel branching were observed after treatments. Alterations in cytokine profile after local PACAP injection further supported the protective role of the peptide. This is the first study to examine the effects of PACAP in ROP. Although the exact mechanism is still not revealed, the present results show that PACAP treatment can ameliorate the vascular changes in the animal model of ROP.Keywords
Funding Information
- OTKA (K104984)
- Arimura Foundation
- Bolyai Scholarship of the Hungarian Academy of Sciences
- PTE AOK Research Grant
- National Brain Research Program (KTIA_13_NAP-A-III/5)
This publication has 44 references indexed in Scilit:
- Intravesical PAC1 Receptor Antagonist, PACAP(6–38), Reduces Urinary Bladder Frequency and Pelvic Sensitivity in NGF-OE MiceJournal of Molecular Neuroscience, 2016
- Pharmacologic interventions for the prevention and treatment of retinopathy of prematuritySeminars in Perinatology, 2016
- Neuroprotection of a Novel Cyclopeptide C*HSDGIC* from the Cyclization of PACAP (1–5) in Cellular and Rodent Models of Retinal Ganglion Cell ApoptosisPLOS ONE, 2014
- Pleiotropic Functions of Pituitary Adenylyl Cyclase-Activating Polypeptide on Retinal Ontogenesis: Involvement of KLF4 in the Control of Progenitor Cell ProliferationJournal of Molecular Neuroscience, 2014
- Influence of Terminal Differentiation and PACAP on the Cytokine, Chemokine, and Growth Factor Secretion of Mammary Epithelial CellsJournal of Molecular Neuroscience, 2013
- Retinopathy of prematurityThe Lancet, 2013
- Comparison between PACAP- and enriched environment-induced retinal protection in MSG-treated newborn ratsNeuroscience Letters, 2010
- Pituitary adenylyl cyclase‐activating polypeptide controls the proliferation of retinal progenitor cells through downregulation of cyclin D1European Journal of Neuroscience, 2010
- Suppression of Rat Retinal Ganglion Cell Death by PACAP Following Transient Ischemia Induced by High Intraocular PressureJournal of Molecular Neuroscience, 2010
- GABAergic amacrine cells and visual function are reduced in PAC1 transgenic miceNeuropharmacology, 2009